TC BioPharm Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Employees (Tables)

12 Months Ended

Dec. 31, 2022

	Year ended December 31,		Year ended December 31,		Year ended December 31,
	2022 Number		2021 Number		2020 Number
Number of employees
Average monthly number or persons (including directors) employed by the Group:
Research and development		70		61		66
Management, administration and operations		9		8		13
Number of employees		79		69		79

Management includes employees who are involved in both research and development and administrative operations.

Schedule of staffing costs

	Year ended December 31,		Year ended December 31,		Year ended December 31,
	2022		2021		2020
	£		£		£
Staff costs – included in research and development
Wages and salaries		3,512,525		2,989,066		3,443,726
Social security costs		432,388		313,138		386,063
Pension costs – defined contribution		156,360		94,938		130,339
Share based payments		403,803		-		316,259
Total staff costs		4,505,076		3,397,142		4,276,387
Staff costs – included in administrative expenses
Wages and salaries		1,586,591		877,752		703,366
Social security costs		249,091		56,646		99,040
Pension costs – defined contribution		59,801		42,034		24,548
Share based payments		719,447		-		256,803
Total staff costs		2,614,930		976,432		1,083,757
Staff costs – combined
Wages and salaries		5,099,116		3,866,818		4,147,091
Social security costs		681,479		369,784		485,102
Pension costs – defined contribution		216,161		136,972		154,887
Share based payments		1,123,250		-		573,062
Total staff costs		7,120,006		4,373,574		5,360,142

Directors’ remuneration	Year ended December 31,		Year ended December 31,		Year ended December 31,
	2022		2021		2020
	£		£		£
Directors’ remuneration in respect of qualifying services		1,203,537		1,046,324		967,651
Directors’ employer’s pension contributions		72,176		15,001		14,376
Directors remuneration		1,275,713		1,061,325		982,027